Policies encouraging price competition in the generic drug market: Lessons from the European experience;Políticas de fomento de la competencia en precios en el mercado de genéricos: lecciones de la experiencia europea

Gaceta Sanitaria

Volumn 24, Issue 3, 2010, Pages 193-199

  Puig Junoy, Jaume ^a  

^a DEPARTMENT OF ECONOMICS AND BUSINESS   (Spain)

Author keywords

Generic drugs; Pharmaceutical expenditure; Price competition; Price regulation; Reference pricing

Indexed keywords

GENERIC DRUG;

ARTICLE; COMMERCIAL PHENOMENA; ECONOMICS; EUROPE; POLICY;

COMMERCE; DRUGS, GENERIC; EUROPE; POLICY;

EID: 77954862691     PISSN: 02139111     EISSN: 15781283     Source Type: Journal    
DOI: 10.1016/j.gaceta.2009.12.003     Document Type: Article

References (23)

1. Kanavos P., Costa-Font J., Seeley E. Competition in off-patent drug markets. Issues, regulation and evidence. Economic Policy 2008, 499-544.
2. Kanavos P. Do generics offer significant savings to the UK National Health Serrvice?. Curr Med Res Opin 2007, 23:105-116.
3. Kanavos P., Taylor D. Pharmacy discounts on generic medicines in France: is there room for further efficiency savings?. Curr Med Res Opin 2007, 23:2467-2476.
4. Borrell J.R., Merino A. Los beneficios de una competencia incipiente: descuentos y bonificaciones a oficinas de farmacia. Anuario de la Competencia 2006, 153-172.
5. Borrell JR, Merino A. Los beneficios de una competencia incipiente: descuentos y bonificaciones a oficinas de farmacia. Comunicación presentada en: XXVII Jornadas de Economía de la Salud; 6-8 junio 2007; A Coruña, España.
6. Puig-Junoy J. Análisis de los descuentos competitivos a las oficinas de farmacia en las compras de medicamentos genéricos. Barcelona: Autoritat Catalana de la Competència. Disponible en: http://www.acco.gencat.cat.
7. European Commission (EC), Competition DG. Pharmaceutical Sector Inquiry [final report 8 July 2009]. Disponible en: http://ec.europa.eu/competition/sectors/pharmaceuticals/inquiry/index.html.
8. Natz A. Rebate contracts: risks and chances in the German generic market. Journal of Generic Medicines 2009, 5:99-103.
9. Adriaen M., de Witte K., Simoens S. Pricing strategies of originator and generic medicines following patent expiry in Belgium. Journal of Generic Medicines 2008, 5:175-187.
10. Anell A. Deregulating the pharmacy market: the case of Iceland and Norway. Health Policy 2005, 75:9-17.
11. Brekke K., Holmas T.H., Straume O.R. Are pharmaceuticals still inexpensive in Norway? A price comparison of prescription-only pharmaceuticals in Norway and 9 western European countries. SNF Report 2009, 07/09. Disponible en: http://www.apotek.no/sw28821.asp?usepf=true.
12. Dalen D.M., Strøm S., Haabeth T. Price regulation and generic competition in the pharmaceutical market. Eur J Health Economics 2006, 7:208-214.
13. Frostelid T, Hansen T, Sveen K. 2007. Norway-Pharma profile. (Actualizado en junio de 2007.) Disponible en: http://ppri.oebig.at/Downloads/Results/Norway_PPRI_2007.pdf.
14. Johnsen J.R. Norway 2006. Health Systems in Transition 2006, 8:1-187.
15. Hakonsen H., Horn A.M., Toverud E.-L. Price control as a strategy for pharmaceutical cost-containment-What has been achieved in Norway in the period 1994-2004?. Health Policy 2009, 90:277-285.
16. Andersson K., Petzold M.G., Sonesson C., et al. Do policy changes in the pharmaceutical reimbursement schedule affect drug expenditures? Interrupted time series analysis of cost, volume and cost per volume trends in Sweden 1986-2002. Health Policy 2006, 79:231-243.
17. Godman B., Wettemark B., Hoffman M., et al. Multifaceted national and regional drug reforms and initiatives in ambulatory care in Sweden: global relevante. Expert Rev Pharmacoeconomics Outcomes Res 2009, 9:65-83.
18. Moïsse P., Docteur E. Pharmaceutical pricing and reimbursement in Sweden 2008, 28. OECD Health Working Papers, Paris, France.
19. Redman T, Höggard MK. Sweden-Pharma profile. (Actualizado en junio de 2007.) Disponible en: http://ppri.oebig.at/Downloads/Results/Sweden_PPRI_2007.pdf.
20. Wettermark B., Godman B., Andersson K., et al. Recent national and regional drug reforms in Sweden. Pharmacoeconomics 2008, 26:537-550.
21. López-Casasnovas G., Puig-Junoy J. Review of the literature on reference pricing. Health Policy 2000, 54:87-123.
22. Faunce T.A., Lofgren H., Harvey K., et al. Tendering for low cost generics in Australia. Health Issues 2006, 87:26-29.
23. Canadian Competition Bureau. 2008. Benefiting from generic drug competition in Canada: the way forward. November. Disponible en: http://www.competitionbureau.gc.ca.